Cargando…

2387. Selecting Clostridium difficile Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial

BACKGROUND: CDC recognizes CDI as an immediate public health threat requiring urgent and aggressive action. Recurrent CDI (rCDI) occurs in up to 30% following initial therapy and 65% following a second recurrence. Perturbation by prior antibiotic use diminishes host colonization resistance allowing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vickers, Richard, Chowdhury, Sumita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254430/ http://dx.doi.org/10.1093/ofid/ofy210.2040

Ejemplares similares

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients
por: Duperchy, Esther, et al.
Publicado: (2018)

668. Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN)
por: Paul, Sumita, et al.
Publicado: (2019)

1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
por: Duperchy, Esther, et al.
Publicado: (2018)

Ridinilazole: a novel antimicrobial for Clostridium difficile infection
por: Cho, Jonathan C., et al.
Publicado: (2019)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
por: Thorpe, Cheleste M., et al.
Publicado: (2018)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

Ridinilazole: a novel, narrow‐spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile
por: Collins, Deirdre A, et al.
Publicado: (2022)

2387. Learning the Influence of Individual Clostridioides difficile Infections
por: Mu, Emily, et al.
Publicado: (2019)

New advances in the treatment of Clostridium difficile infection (CDI)
por: Hedge, Dennis D, et al.
Publicado: (2008)

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
por: Vickers, Richard J, et al.
Publicado: (2017)

2365. Volatile Metabolite-Based Detection of Clostridium difficile Infection (CDI)
por: Aloum, Obadah, et al.
Publicado: (2019)

Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile
por: Collins, Deirdre A, et al.
Publicado: (2020)

Use of Electronic Data to Identify Risk Factors Associated with Clostridium difficile Infection (CDI) and to Develop CDI Risk Scores
por: Aukes, Laurie, et al.
Publicado: (2017)

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
por: Mason, Clive, et al.
Publicado: (2021)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
por: Qian, Xi, et al.
Publicado: (2020)

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases
por: Olsen, Margaret A., et al.
Publicado: (2016)

527 Age-Related Changes in the Incidence of Community-Associated Clostridium Difficile Infection (CDI)
por: Faden, Howard
Publicado: (2014)

485. On- and Post-Antibiotic Effects on the Risk of Hospital-Acquired Clostridium difficile Infection (CDI)
por: Stevens, Vanessa, et al.
Publicado: (2018)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

973 Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients
por: Stevens, Vanessa, et al.
Publicado: (2014)

467. Investigation of a Clostridium difficile Infection (CDI) Outbreak in a Community Teaching Hospital
por: Parker, Laura, et al.
Publicado: (2018)

PROJECT ADMINISTRATION AGREEMENT KN 2387 FP
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2014)

1653 Results of a Treatment Protocol Encouraging First-Line Use of Fidaxomicin for Select Patients with Clostridium difficile Infection (CDI)
por: Navalkele, Bhagyashri, et al.
Publicado: (2014)

Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study
por: Swale, Andrew, et al.
Publicado: (2014)

Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
por: Fareed, Shaaz, et al.
Publicado: (2018)

Are Patients with Prior Clostridium difficile Infection (CDI) a Potential Source of Transmission during Hospital Admissions?
por: Gonzalez-Orta, Melany, et al.
Publicado: (2017)

Predictors of 30-day All-cause Mortality in Veterans with First Recurrence of Clostridium difficile Infection (CDI)
por: Morrill, Haley, et al.
Publicado: (2017)

1980. Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed Clostridium Difficile Infection (CDI)
por: Tirmizi, Samad, et al.
Publicado: (2018)

1122. Evaluation of Fecal Microbiota Transplant (FMT) in Elderly Patients With recurrent Clostridium difficile Infection (CDI)
por: Hassoun, Ali, et al.
Publicado: (2018)

Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
por: Talbot, George H., et al.
Publicado: (2019)

Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI
por: Navalkele, Bhagyashri D., et al.
Publicado: (2016)

P028: Examining the relationship between fluoroquinolone use and Clostridium difficile infections (CDI): a meta-analysis
por: Formanek, MB, et al.
Publicado: (2013)

Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients: An Observational Cohort Study
por: Stevens, Vanessa W., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6ncrsv3if0celv976cm4hb4svq